

## Introduction

Two types of cells have been characterized as pluripotent stem cells: human embryonic stem cells (hESCs) and the more recently described induced pluripotent stem cells (iPSCs). Pluripotency means that these cells have the ability to form all the cells and tissues of the human body. hESC and iPSC differentiation into blood cells is particularly useful in studying the mechanisms of blood diseases and cell transfusion therapies.

To better understand the potential of these cells to specifically produce blood cells, it is necessary to define an efficient and reproducible system of differentiation. Previously, our and other groups have used a stromal cell co-culture method to support blood development from hESCs. In these current studies, we are employing a stromal-free and serum-free differentiation method that may facilitate clinical translation of hESC- and iPSC-derived cells. This method involves forced aggregation of defined numbers of undifferentiated hESCs or iPSCs in 96-well plates by centrifugation to form embryoid bodies (spin EBs) of a uniform size. We examine this method's potential to derive blood precursor cells and mature blood lineage cells from both hESCs and iPSCs.

## Methods

### Spin-EB Differentiation: Stage I and II

3,000 undifferentiated H9 (hESCs) or iPSCs were plated in each well of a round-bottom 96-well plate. The cells were forced to aggregate by centrifugation – forming “Spin EBs” of uniform size. The spin EBs were cultured for 8-12 days in a serum-free medium containing a cocktail of human cytokines (SCF, BMP4, VEGF) to induce production of blood precursor cells.

After 8 days of differentiation in Stage I, EBs were transferred to 24-well plates for a second stage of differentiation to promote generation of mature blood lineage cells. In Stage II differentiation, EBs from stage I were cultured in a serum-free medium containing a cocktail of human cytokines (SCF, VEGF, IL-3, IL-6, TPO, EPO). Cells remained Stage II for 4 weeks and were harvested regularly for phenotypic analysis.

### Flow Cytometry Analysis of Differentiated hESCs and iPSCs

Stage I or II differentiated cells were harvested at regular time points for flow cytometric analysis. Cells were dissociated and stained with fluorescently-tagged antibodies to detect common markers of blood lineage development including CD34-allophycocyanin (APC), CD31-phycoerythrin (PE), CD43-PE, and CD45-PE in Stage I. Stage II cells were stained with antibodies to detect more mature blood cell phenotypes, including CD45-APC/PE, GlyA-PE, CD34-APC and CD33-PE.

### Hematopoietic Colony Assay of Differentiated hESCs and iPSCs

3 x 10<sup>4</sup> cells harvested from day 11 Stage I Spin-EBs were plated in 35mm petri dishes in MethoCult GF+ (StemCell Technologies) semi-solid medium containing hematopoietic growth factors. Colony forming units were scored after 11 days of incubation.

**Figure 1: Spin EB differentiation scheme.** hESC and iPSCs are enzymatically dissociated to a single cell suspension and plated into 96-well round bottom plates at 3,000 cells/well. In Stage I, cells are aggregated by centrifugation to induce embryoid body formation. Stage I Spin-EBs are incubated at 37°C, 5% CO<sub>2</sub> for 8-12 days in a serum-free media with cytokines/growth factors that promote generation of blood precursor cells. In Stage II, EBs are transferred to adherent 24-well plates with a different set of cytokines/growth factors to promote further differentiation into mature blood lineage cells.






Table 1: Cell surface markers for blood lineage cells

CD Antigen	Cellular Distribution
CD31	blood precursors, monocytes, platelets, granulocytes, endothelial cells
CD33	myeloid precursors, monocytes, granulocytes
CD34	blood precursors
CD43	blood precursors, leukocytes
CD45	blood cells (pan-blood lineage marker)
CD235a (GlyA)	erythrocytes

## Results

•Both hESCs (H9) and iPSCs (Lako) produce CD34<sup>+</sup>CD31<sup>+</sup> and CD34<sup>+</sup>CD45<sup>+</sup> blood precursor cells in the serum-free and stromal-free spin EB system, as measured by flow cytometry (Fig 2 A & B).

•Generation of blood precursor cells in Stage I spin EB differentiation was confirmed by hematopoietic CFU assay for both hESCs and iPSCs (Fig 2C).

•When transferred into a second stage of differentiation, blood cell precursors generated through spin EB culture of hESCs and iPSCs further differentiate into mature blood lineage cells, including erythroid (CD45<sup>+</sup>GlyA<sup>+</sup>; Fig 3A & B) and myeloid (CD45<sup>+</sup>CD33<sup>+</sup>; Fig. 3C) lineages.

## Conclusion

The results support the use of the Spin-EB protocol for efficient differentiation of hESCs and iPSCs. Cells derived from both hESCs and iPSCs expressed markers of blood precursor cells and generated mature blood lineage cells in a second stage of differentiation.

Future studies will use this spin EB method to better define the culture conditions necessary to generate lymphocyte precursors and mature lymphocytes (T, B, and NK cells) from hESCs and iPSCs.

## Acknowledgements

Funding Provided By: NIH/NHLBI

Melinda Hexum: For invaluable guidance and help with experimental set-up and maintenance.

Xinghui Tian, PhD.: For training and assistance with this poster.